Search

The article focuses on the investigation of MAGE-A gene and protein expression in urothelial and non-small cell lung carcinomas. Topics include the assessment of MAGE-A3/A6 expression profiles and immune landscape in these cancers, the evaluation of immune marker co-expression such as PD-L1, and the stability of MAGE-A expression in response to checkpoint inhibitor therapy.

The article presents an interim analysis from the Hamad Medical Corporation on the use of beta-blockers, specifically propranolol, in treating traumatic brain injury (TBI). Topics include the impact of propranolol on inflammatory markers and biomarkers, the correlation between high-sensitivity troponin T and injury severity, and the potential benefits of beta-blockers in managing TBI inflammation.

The article announces the issuance of a patent for a method of sensing cardiac signals using leads implanted in the epidural space, and assigned to Medtronic Inc. Topics discussed include the scope of medical devices for electrical stimulation, various therapeutic applications like deep brain stimulation and spinal cord stimulation, and the selection of programmable parameters for electrical therapy.

The article focuses on a U.S. patent application filed by Regeneron Pharmaceuticals Inc. for methods to improve the generation of genetically modified rat embryonic stem (ES) cells. It explains that the patent outlines compositions and techniques for enhancing the frequency of germline transmission of genetic modifications in rats, including the use of specific culture conditions and feeder cells.

The article reports on a U.S. patent application filed by Nano Ghost Ltd. for a novel method to produce spherical particles from mesenchymal stem cells (MSCs) for targeted cancer therapy. It explains how these nanoghosts are created by isolating and downsizing intact MSC membranes, which then encapsulate therapeutic agents like mRNA for improved drug delivery. The patent highlights the particles' biocompatibility and long circulation times, making them ideal for cancer treatment.

The article focuses on mitochondrial markers for neurodegenerative diseases. Topics discussed include the identification of methylation patterns in mitochondrial deoxyribonucleic acid (DNA), the association of these patterns with Alzheimer's disease (AD) and Parkinson's disease (PD), and various methods for detecting these epigenetic changes to aid in diagnosis and prognosis.

The article reports that Celgene Corporation received a patent for methods to treat systemic lupus erythematosus (SLE) and predict therapy sensitivity using biomarkers (U.S. Patent and Trademark Office Patent No. 12064437). Topics include determining treatment doses based on IKZF3 (IKAROS Family Zinc Finger 3) gene expression, using specific compounds for SLE, and personalized therapy benefits.

The article reports on a patent application for a blood-based assay that detects tauopathy and amyloidogenic diseases using p217+tau peptides in plasma samples. Topics include the assay method involving capture and detection antibodies, applications for diagnosing Alzheimer's Disease and other tauopathies, and the advantages of a non-invasive plasma test over traditional cerebrospinal fluid analysis.

The article reports that a patent has been issued for a method using digital biomarkers to evaluate information processing speed, focusing on neurological assessments and cognitive impairment. Topics include the application of the method in drug research, diagnostics, and the use of mobile devices for assessing cognitive function.

A patent application has been submitted by researchers from Colgate-Palmolive for the development of salivary biomarkers to detect and diagnose gingivitis. Gingivitis is a common inflammatory disease that can progress to periodontitis if left untreated, leading to tooth loss and potential systemic health issues. Currently, the gold standard for detection is a comprehensive periodontal exam, but the development of objective biomarkers could improve early detection and monitoring. The patent application outlines methods for diagnosing gingivitis, monitoring treatment response, and treating the condition. [Extracted from the article]

A patent application by Boston Scientific Scimed Inc. has been made available online for a medical device designed to improve radiation therapy for prostate cancer patients. The device is a urinary catheter with two balloons that can be positioned within the urethra. One balloon can be filled with barium sulfate to block radiation from reaching the penile bulb, reducing the risk of erectile dysfunction. The device also includes markers and a third balloon for additional functionality. This invention aims to address the need for systems, devices, and methods to protect the penile bulb during radiation treatment for prostate cancer. [Extracted from the article]

A recent study conducted by AbbVie Inc. investigated the effects of the drug Cedirogant on the pharmacokinetics of two statin drugs, rosuvastatin and atorvastatin. The study found that Cedirogant increased the maximum plasma concentration and area under the plasma concentration curve of rosuvastatin, while having minimal effect on atorvastatin. The researchers used coproporphyrin-I (CP-I) as a biomarker to assess the impact of Cedirogant on organic anion transporting polypeptide (OATP) 1B. The study concluded that CP-I can be used to understand the mechanisms of complex drug-drug interactions involving multiple transporters and enzymes. [Extracted from the article]

Myriad Women's Health Inc. has submitted a patent application for a method called "Combinatorial DNA Screening" that aims to accurately detect disease-associated mutations, including those found in cancer and fetal genetic disorders. The method involves using probes and nucleic acid samples to identify specific mutations in tumor tissue, which can then be used to determine the proportion of circulating tumor DNA in a patient's cell-free DNA. The patent application provides detailed information on the probes, nucleic acid samples, sequencing methods, and enrichment techniques used in the method. It also describes a method for preparing a DNA fraction enriched with circulating tumor DNA from cancer patients, which can be used to detect relapse or monitor response to treatment. [Extracted from the article]

A patent has been issued for methods and compositions for synthetic biomarkers. The patent describes a method for detecting cancer in its earliest stages by administering a composition that induces the expression of a biomarker in diseased cells. The biomarker is then detected and used to determine if the subject has the diseased cells with an accuracy of at least 70%. The patent also describes a method for treating cancer by administering a composition that induces the expression of a therapeutically effective agent in diseased cells. The patent provides various embodiments and compositions for detecting and treating cancer using synthetic biomarkers. [Extracted from the article]

A study conducted by F. Hoffmann-La Roche Ltd. in Basel, Switzerland, explores the use of biomarkers in the early clinical development of cancer immunotherapies. The research highlights the importance of biomarkers in various aspects of drug development, including demonstrating the mechanism of action, optimizing dosage, managing adverse reactions, and prioritizing patient indications. The study discusses statistical methods for establishing the prognostic and predictive aspects of biomarkers and linking changes in biomarkers to clinical efficacy. This review is aimed at drug developers and data scientists interested in the strategic usage and analysis of biomarkers in the context of immunotherapies. [Extracted from the article]

The article focuses on a patent application related to a discovery platform for understanding disease phenotypes through advanced computational methods. Topics include identifying covariants influencing disease progression, utilizing machine learning models for analyzing phenotypic data, and integrating genomic and clinical data to optimize drug development and clinical trials.

The article focuses on new findings from Alcon Laboratories Inc. regarding the potential of tear A-synuclein as a biomarker for Parkinson's disease. Topics include the reliability of tear A-synuclein in early diagnosis, the outcomes of a systematic review and meta-analysis, and its implications for future diagnostic practices.

Morphic Medical Inc. has been issued a patent for methods of assessing treatment with a gastrointestinal implant. The patent aims to identify individuals who are at risk of developing complications from treatment with gastrointestinal implants, such as gastrointestinal sleeves, which are used to treat metabolic disorders like type 2 diabetes and obesity. The methods involve measuring biomarkers in samples from individuals to determine their risk of complications and guide subsequent treatment decisions, including the removal of the implant. The patent addresses the need for non-surgical methods to treat metabolic disorders while minimizing complications. [Extracted from the article]

This article explores the impact of inflammation on lipid and lipoprotein metabolism in patients with rheumatoid arthritis (RA). Inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a), play a role in altering lipid and lipoprotein profiles in RA patients. The article discusses the effects of C-reactive protein (CRP) and myeloperoxidase (MPO) on lipoprotein functionality and the dysregulation of lipid and lipoprotein profiles in RA patients. These abnormalities contribute to an increased risk of cardiovascular disease (CVD) in RA patients. The article suggests that further research is needed to understand the mechanisms underlying these dysfunctions and develop targeted therapies to address them. [Extracted from the article]

The article focuses on a patent application for a "Discovery Platform" aimed at improving disease research and drug development through advanced computational analysis. Topics include the use of unsupervised machine learning to analyze phenotypic and genetic data, the platform's potential for identifying disease targets and predicting disease progression, and its application in optimizing clinical trials and therapeutic outcomes.

The article focuses on a patent application for a machine-learning-enabled system designed to discover predictive biomarkers and stratify patients using standard-of-care data. Topics include leveraging machine learning to integrate medical imaging and molecular analyte data, addressing challenges in biomarker discovery and clinical trial design, and improving patient stratification for precision medicine.

The article focuses on a newly issued patent for a light-based dental treatment device designed to enhance endodontic procedures. Topics include its application of electromagnetic energy to sterilize and regenerate dental tissues, the use of specific wavelengths of light, and its potential benefits over traditional chemical disinfection methods, including reduced risks and improved efficacy in treating infected root canals.

The article focuses on TNF Pharmaceuticals' preparation to advance its lead clinical program, MYMD-1, through mid-stage trials targeting age-related decline. Topics include the drug's potential as the first oral TNF-alpha inhibitor for sarcopenia, ongoing Phase 2 trials in additional inflammatory conditions, and the company's strategy for growth and commercialization.

A recent study conducted by researchers at Medtronic explores the potential use of spinal cord stimulation (SCS) leads as a means of recording cardiac electrograms. The study aimed to evaluate the feasibility of using SCS leads to track cardiac activity and compare it to measurements taken with wearable devices. The results showed that the quality of signals recorded by the SCS leads was acceptable for detecting R-peaks, and the recordings enabled more reliable beat detection compared to wearables. This research suggests that an implanted SCS system could potentially serve as a means of automated therapy by tracking biomarkers of a patient's overall health state without the need for additional external devices. [Extracted from the article]

A patent application by inventors Arnon Chait and Boris Y. Zaslavsky, assigned to Cleveland Diagnostics Inc., describes methods and devices for analyzing species to determine diseases. The invention involves partitioning a biological fluid in an aqueous two-phase system and assaying the aqueous phases for a plurality of analytes. By comparing the calculated partition coefficients of the analytes with reference values, the presence or risk level of a disease, such as cancer, can be determined. The liquid partitioning system includes two or more liquid phases that are substantially immiscible, and the concentrations of the species in the liquid phases are related to the presence or absence of the disease. [Extracted from the article]

A patent has been issued for liposomal compositions and their uses. Liposomes are lipid vesicles that can encapsulate both hydrophilic and hydrophobic compounds and are commonly used in drug delivery systems. In cancer therapy, liposomes are popular drug carriers due to their ability to accumulate in tumor cells. This patent focuses on the use of liposomes composed of whole cell membrane fractions, particularly from stem cells, as a targeted delivery vehicle for cancer therapy. The patent describes methods for producing these liposomes and encapsulating pharmaceutical agents within them. [Extracted from the article]

A patent has been issued to Wellsim Biomedical Technologies Inc. for a method of diagnosing diseases based on circulating extracellular vesicles (EVs). EVs are cell-derived vesicles found in various bodily fluids and play a role in disease progression. The method involves incubating the EVs with detection antibodies and a capture antibody immobilized on a substrate, and then detecting disease-specific antigens on the surface of the EVs. This method aims to provide a less expensive, easy-to-operate, highly sensitive, and specific diagnostic tool. The patent also mentions the potential application of this method in diagnosing Alzheimer's disease. [Extracted from the article]

A patent has been issued for the administration and monitoring of nitric oxide (NO) in ex vivo fluids. The patent describes methods and systems for administering NO-containing gas directly to ex vivo fluid and monitoring NO and/or a NO marker in the fluid or in tissues or organs that receive the fluid. The methods and systems have applications in preventing and treating ischemia-reperfusion injury and preventing blood clots in an ECMO circuit. The patent also discusses the use of NO in preserving organs and biological materials for transplantation. [Extracted from the article]

A recent study conducted by Takeda Development Center Americas Inc. has focused on Gaucher's disease, a rare genetic disorder caused by glucocerebrosidase deficiency. The study aimed to identify potential protein biomarkers that could predict the early diagnosis of skeletal complications in Gaucher's disease patients using artificial intelligence. Through their research, the team identified 18 potential candidates, including PDGFB, IL1R2, PTH, and CCL3, which could be easily measured in blood. This study provides a novel tool for discovering new protein biomarkers to support clinicians in making informed decisions regarding skeletal complications in Gaucher's disease patients. However, further confirmation through in vitro and/or in vivo studies is necessary. [Extracted from the article]

The patent application by Hologic Inc. outlines a system and method for generating synthetic breast tissue images that aim to improve the clarity and accuracy of imaging. By suppressing high-density elements, such as shadows caused by imaging objects in or on breast tissue, the system produces clearer images. The system utilizes differential or multi-flow image processing to generate synthesized composite images that eliminate or reduce shadow artifacts while maintaining or enhancing other aspects of the images. The patent application provides detailed claims and technical specifications for the system, which can generate 2D synthesized images based on 2D or 3D image sets. [Extracted from the article]

OnPoint Medical Inc. has been issued a patent for a system that allows for the real-time augmented reality guidance of surgical procedures using head-mounted displays. The system includes a head-mounted display, computer processors, cameras, and fiducial markers that track the movement of the display. The system can generate a virtual display of surgical tools or anatomical structures that is superimposed onto the patient's anatomy within the tracked movement range of the head-mounted display. The patent was filed on December 6, 2021, and published online on August 6, 2024. [Extracted from the article]

A patent has been issued to Alcon Inc. for a head tracking control system for ophthalmic surgery. The system includes markers placed on the surgeon's head, an infrared camera, and an intelligent tracking system. The system detects the movement of the markers and determines if it corresponds to the defined head movement of the surgeon. If it does, the system controls the ophthalmic surgical microscope. The system aims to improve visualization during ophthalmic surgery and reduce surgical errors. [Extracted from the article]

A patent application titled "Osteotomy Guide" has been published online by the US Patent and Trademark Office. The inventors of the guide, Daniel E. Free, Paul Luttrell, Jesse G. Moore, Erin Muller, and Joseph Ryan Woodard, have developed a guide for bone cuts in corrective surgery for hallux valgus (bunion). The guide is designed to minimize collateral tissue damage and scarring, reduce recovery time, and ensure the incision avoids damage to nerves, connective tissue, and the blood supply of the metatarsal. The patent application provides detailed descriptions and claims for various embodiments of the guide. The assignee for this patent application is Wright Medical Technology Inc. [Extracted from the article]

Xencor Inc. has filed a patent application discussing the need for targeted agents to treat systemic lupus erythematosus (SLE), an incurable autoimmune disease. The application proposes a method for determining the efficacy of a human anti-CD19 antibody in treating SLE based on the expression of specific biomarkers. If the biomarkers show increased expression in a blood sample, the antibody therapy can be administered. The patent application also mentions various biomarkers that can be used to identify subjects with increased expression, with the aim of improving therapeutic efficacy and determining treatment susceptibility for autoimmune diseases. [Extracted from the article]

A recent study conducted by Genentech Inc. has explored the use of deep neural nets to map image features to gene expression, specifically in relation to biomarkers. The study introduces MOSBY (Multi-Omic translation of whole slide images for Spatial Biomarker discoverY), a model that extracts improved image features and learns a mapping between image and bulk omic profiles. MOSBY has been validated with spatial transcriptomic and CD8 IHC image data, and has demonstrated the ability to identify and validate clinically relevant spatial biomarkers. The study highlights the potential of MOSBY in unraveling novel insights in cancer biology and informing clinical decision-making. [Extracted from the article]

A new editorial published in Aging discusses the use of DNA methylation-based epigenetic clocks as biomarkers of biological age in human health. The editorial highlights the need to better understand the underlying mechanisms of these clocks and their associations with health outcomes. Researchers from various institutions explored the association between immune cell composition and epigenetic age acceleration (EAA) in both healthy and diseased populations. Their work utilized high-resolution methylation cytometry in blood samples and sheds light on the complex interplay between immune cells and epigenetic aging. [Extracted from the article]

A new report from Janssen Research & Development LLC explores the potential association between vitamin D-related biomarkers and hypertension. The study found that there was no significant association between baseline plasma 25(OH)D or parathyroid hormone (PTH) levels and the risk of hypertension in middle-aged and older men and women. The researchers concluded that vitamin D may not play a significant role in preventing hypertension through the down-regulation of the renin-angiotensin system. This information is valuable for individuals conducting research on hypertension and its potential risk factors. [Extracted from the article]